SpringWorks Therapeutics, Inc.: management transactions · United States · SEC (Form 4)

About SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics, Inc. is a U.S.-listed biopharmaceutical company traded on the NASDAQ under the ticker SWTX. Founded in 2017 and headquartered in Stamford, Connecticut, the company was built around a focused strategy: developing and commercializing medicines for underserved rare diseases and selected cancers. Its evolution from a development-stage biotech into a commercial-stage rare-disease oncology company gives it a profile that sits between innovative biotech and specialty pharma. ([stockanalysis.com](https://stockanalysis.com/stocks/swtx/company/?utm_source=openai)) SpringWorks’ business model is anchored in targeted oncology and rare disease medicine. The company markets OGSIVEO® (nirogacestat), approved in the United States for adult patients with progressing desmoid tumors who require systemic treatment, and GOMEKLI™ (mirdametinib), approved for adults and pediatric patients aged 2 years and older with symptomatic plexiform neurofibromas in neurofibromatosis type 1 (NF1) that are not amenable to complete resection. These two products are the company’s main commercial and clinical pillars, and they give SpringWorks a differentiated position in high-unmet-need orphan indications. ([ir.springworkstx.com](https://ir.springworkstx.com/news-releases/news-release-details/springworks-therapeutics-announces-fda-approval-ogsiveotm?utm_source=openai)) From a competitive standpoint, SpringWorks operates in a specialized niche where clinical differentiation, regulatory execution, and orphan-drug economics matter more than broad primary-care scale. The company describes a diversified targeted oncology pipeline spanning solid tumors and hematologic cancers, with programs across preclinical, early-stage, and advanced clinical development. That pipeline breadth reduces single-asset dependence while preserving a strong focus on genetically defined diseases and rare oncology settings, where the addressable patient populations are smaller but medically urgent. ([springworkstx.com](https://springworkstx.com/pipeline/?utm_source=openai)) Geographically, the commercial footprint is still primarily centered in the United States, where both OGSIVEO and GOMEKLI are approved. At the same time, SpringWorks has pursued international expansion opportunities, including regulatory activity in Europe for mirdametinib, indicating that management has viewed the platform as potentially broader than a purely U.S. launch story. In practical terms, however, the company has remained most visible as a U.S. oncology biotech with a domestic commercialization base and select global ambitions. ([ir.springworkstx.com](https://ir.springworkstx.com/news-releases/news-release-details/springworks-therapeutics-announces-fda-approval-gomeklitm/?utm_source=openai)) Recent milestones have been highly significant. In February 2025, the FDA approved GOMEKLI for NF1-PN, following the earlier FDA approval of OGSIVEO in 2023. In April 2025, Merck KGaA, Darmstadt, Germany announced an agreement to acquire SpringWorks Therapeutics, underscoring the strategic value of its approved assets and pipeline. For investors, SpringWorks represents a U.S.-listed NASDAQ biopharma story with validated clinical assets, a specialty oncology focus, and a clear recent corporate catalyst through acquisition. ([ir.springworkstx.com](https://ir.springworkstx.com/news-releases/news-release-details/springworks-therapeutics-announces-fda-approval-gomeklitm/?utm_source=openai))